Recent Financings Of Private Companies, October 2013
• By Deanna Kamienski, Beth Allan, Andrea Mancini, Amanda Micklus, Maureen Riordan, and Theresa Surprenant
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Device, and Pharmaceuticals sector. This month’s column covers deals announced August through September 2013.
Carmenta Bioscience brings in $2mm through its seed round
Carmenta Bioscience Inc. (prenatal tests) raised $2mm through its seed round. Company management, Life Science Angels, and individual scientists...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
